USPTO Patent Applications - Peptides (C07K)

US Patent Application for Antigen Production Methods

The USPTO has published a new patent application (US20260085100A1) from The Wistar Institute of Anatomy and Biology detailing methods for manufacturing individualized vaccines. The application focuses on nucleic acid molecules encoding neoantigens specific to tumor antigens for use in subject immunization.

Novel Platelet Derived Growth Factor Peptide Mimetic for Cardiac Repair

The USPTO has published a patent application (US20260085101A1) for a novel platelet-derived growth factor peptide mimetic designed for cardiac repair, particularly post-infarction. The application details specific compounds, their preparation, and methods of use.

Patent Application for Synthetic Promoters and Circuits in Cancer Cells

The USPTO has published a patent application (US20260085102A1) for nucleic acid molecules designed to specifically express sequences of interest in cancer cells. The application details synthetic promoters and circuits for use in cancer treatment.

Long-acting insulin compound for treating diabetes

The USPTO has published a patent application (US20260085103A1) for a long-acting insulin compound designed for treating diabetes. The application details the compound's use in pharmaceutical compositions for conditions including type-I, type-II, and gestational diabetes.

Patent Application for Detecting Immune Cells Using Fusion Proteins

The USPTO has published a new patent application (US20260085104A1) detailing fusion proteins for detecting and isolating immune cells. The application, filed by Patrick Schlegel, describes specific fusion proteins involving a dysfunctional purinergic P2X7 receptor epitope and an antibody Fc region.

MAGEA4 Specific T Cell Receptors Patent Application

The USPTO has published a patent application (US20260085105A1) filed by Amgen Inc. for recombinant T-cell receptors designed to selectively recognize MAGE-A4-derived peptides. The application details screening for cross-reactivity and alloreactivity.

Chimeric Antigen Receptor System for Signalling

The USPTO has published a new patent application, US20260085106A1, detailing a chimeric antigen receptor (CAR) system. This system is designed to control signalling based on the presence or absence of a specific agent, potentially impacting the development of targeted therapies.

Ginkgo Bioworks Patent for Protein Production and Secretion Systems

The USPTO has published a new patent application (US20260085107A1) filed by Ginkgo Bioworks, Inc. The patent describes expression systems for enhanced production and secretion of proteins, including specific examples like bovine lactoferrin. This application is part of the ongoing patent process for novel biotechnological methods.

Methods for Separating Chelator from Mixture Using Chromatography

The USPTO has published a new patent application, US20260085108A1, detailing methods for separating a chelator from a mixture using chromatography. This application, filed on September 8, 2023, by inventors Jason Huang and Qiang Li, describes techniques useful in adjusting the concentration of chelators in protein compositions.

Patent Application: Filtration Condition Evaluation and Cell Product Production

The USPTO has published a new patent application (US20260085109A1) from Asahi Kasei Life Science Corporation detailing a method for evaluating filtration conditions and producing cell products. The application was filed on November 14, 2023, and published with a projected application date of March 26, 2026.

Patent Application: Production Method for Product to Prevent Membrane Clogging

The USPTO has published a patent application from FUJIFILM Corporation detailing a production method for a product that aims to prevent membrane clogging during cell culture. The method involves specific mathematical expressions related to poloxamer concentration, product concentration, and hydrophobicity index to optimize the cell culture process.

Patent Application for SLIT2 Related Compositions and Methods

The USPTO has published a new patent application (US20260085111A1) filed by EVEREST MEDICINES (SINGAPORE) PTE. LTD. The application relates to antibodies that bind to SLIT2 and related substitution mutants, including their manufacture and use.

Patent Application for Free LIGHT Detection and Treatment

The USPTO has published a patent application (US20260085112A1) from Avalo Therapeutics, Inc. for methods of detecting and treating conditions associated with elevated free LIGHT using anti-LIGHT antibodies. The application covers methods for diagnosing conditions like acute lung injury, ARDS, and Crohn's Disease.

All-in-one Agonistic Antibodies Patent Application

The USPTO has published a patent application (US20260085113A1) filed by Hoffmann-La Roche Inc. on October 2, 2025. The application describes antigen binding molecules comprising biparatopic target-binding domains and cytokine receptor-binding domains designed to selectively activate cytokine receptors.

Patent Application: Multispecific Binding Constructs Against Checkpoint Molecules

The USPTO has published a new patent application (US20260085121A1) from Compass Therapeutics, LLC, detailing multispecific binding constructs against checkpoint molecules. The application focuses on compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression, specifically blocking interactions between PD-1 and its ligand.

Patent Application: Antibodies Binding Human 4Ig-B7H3

The USPTO has published a new patent application (US20260085122A1) filed by BeOne Medicines I GmbH. The application relates to antibodies or antigen-binding fragments thereof that bind to human 4Ig-B7H3.

Patent Application: Anti-FGFR2 Antibodies with Chemotherapy for Cancer Treatment

The USPTO has published patent application US20260085123A1, filed by Five Prime Therapeutics, Inc. The application details the use of anti-FGFR2 antibodies in combination with mFOLFOX6 chemotherapy for treating certain cancers.

Patent Application for Tenosynovial Giant Cell Tumor Treatment

The USPTO has published a patent application (US20260085124A1) detailing compositions and methods for treating tenosynovial giant cell tumor using intra-articular delivery of anti-CSF1R antibodies. The application, filed by Kirk William Johnson, focuses on sustained drug exposure within joints.

Patent Application for Apelin Receptor Binding Polypeptides and Methods

The USPTO has published a new patent application (US20260085125A1) for apelin receptor binding polypeptides and methods of treatment. The application was filed on November 25, 2025, and details antibodies and polypeptides that specifically bind to the apelin receptor (APJ).

Patent Application for Agonistic TNF Receptor Binding Agents

The USPTO has published a new patent application, US20260085126A1, for agonistic TNF receptor binding agents. The application, filed on August 27, 2025, by inventors including Ugur Sahin, details binding agents for TNF superfamily receptors and their potential medical uses.

Bispecific Antibody Targets TIM-3 and CD39 for Cancer

The USPTO has published a patent application (US20260085127A1) for a bispecific antibody designed to target both TIM-3 and CD39 antigens. This antibody aims to enhance immune activity against cancer cells and is intended for cancer treatment.

Anti-CD157 Antibodies, Fragments, Compositions, and Methods

The USPTO has published a patent application (US20260085128A1) detailing anti-CD157 antibodies, antigen-binding fragments, compositions, and methods for their use. The application was filed on July 18, 2023, and describes potential diagnostic reagents and kits.

CD163 Binding Protein Patent Application

The USPTO has published a patent application (US20260085129A1) filed by ECO ANIMAL HEALTH LTD. on October 11, 2023. The application relates to an antibody that binds to porcine CD163, specifically its membrane-bound form.

Takeda's Monoclonal Antibody Inhibitor of Factor XIIa Patent Application

The USPTO has published a patent application from Takeda Pharmaceutical Company Limited for a monoclonal antibody inhibitor of Factor XIIa. The application, filed on August 12, 2025, describes methods for treating diseases associated with Factor XII, including hereditary angioedema and ocular diseases.

Patent Application: Bispecific Antibodies and Uses Thereof

The USPTO has published a new patent application (US20260085131A1) for bispecific antibodies and their uses. The application, filed on August 20, 2025, describes antibodies that bind to two different antigens with varying affinities.

Heterodimeric Human IgG1 Polypeptides with Isoelectric Point Modifications

The USPTO has published a new patent application, US20260085132A1, titled 'Heterodimeric Human IgG1 Polypeptides with Isoelectric Point Modifications'. The application details methods for purifying desired heterodimer immunoglobulin variants from contaminating homodimer variants by modifying isoelectric points.

Polyproline Nanocage Compound and Manufacturing Method

The USPTO has published a patent application for a polyproline nanocage compound and its manufacturing method. The application details a compound comprising two cyclic peptide scaffolds connected by molecules, with each scaffold containing polyproline helix rods and turn-angle molecules. This is a routine publication of a new patent application.

USPTO Patent Application for Fusion Polypeptides

The USPTO has published a new patent application (US20260085300A1) detailing systems and compositions for fusion polypeptides and their methods of use in regulating target genes. The application was filed on October 27, 2023, by inventors Thomas Blair Gainous, Xiao Yang, Giovanni Carosso, Lei S. Qi, and Daniel O. Hart, II.

Base Editing of Plant Cell Organelle DNA

The USPTO has published a patent application (US20260085323A1) detailing a method for base editing plant cell organelle DNA. The application, filed by the Institute for Basic Science, describes a composition and method for editing adenine to guanine and cytosine to thymine in plant cell organelle DNA.

Metabolic Selection via Serine Biosynthesis Pathway Patent Application

The USPTO has published a new patent application, US20260085327A1, related to metabolic selection via the serine biosynthesis pathway. The application details an isolated mammalian cell with reduced expression of Phosphoserine Phosphatase (PSPH) and its use in recombinant protein production.

Karyocreate Patent Application US20260085330A1 Details CRISPR Technology

The USPTO has published patent application US20260085330A1 from Karyocreate detailing CRISPR technology for inducing aneuploidy. The application, filed on September 8, 2023, describes fusion proteins and guide RNAs that interfere with chromosome segregation.

Cell Culture Method Suppressing Foam Aggregates

The USPTO has published a new patent application (US20260085282A1) from FUJIFILM Corporation detailing a cell culture method. The method aims to suppress foam aggregate formation by adjusting poloxamer concentration or foam liquid viscosity during cell culture at high densities.

Patent Application for Endoglin Antibodies Detecting Cancer Splice Variants

The USPTO has published a patent application (US20260086096A1) for endoglin antibodies designed to detect cancer splice variants. The application, filed by Nam Yong Lee, details methods and compositions for improved cancer diagnosis.

USPTO Patent Application for Peptoid Nucleic Acid Delivery

The USPTO has published a patent application (US20260083769A1) detailing novel hydroxyalkyl-capped cationic peptoids for nucleic acid delivery. The application, filed by inventors from various institutions, describes compositions and methods for delivering polyanionic compounds to cells and eliciting immune responses.

USPTO Patent Application: CD70 Antibody Drug Conjugates

The USPTO has published a new patent application (US20260083853A1) detailing CD70 antibody drug conjugates for treating cancer and autoimmune diseases. The application was filed on October 25, 2023, by inventors Xiao Shang and others.

USPTO Patent Application: Antibody Conjugates with Bis-MSPT Linker

The USPTO has published a new patent application (US20260083854A1) detailing antibody conjugates that utilize a bis-MSPT linker. The application, filed by inventors Riazul Alam, Guillermo S. Cortez, and Yan Wang, describes pharmaceutical compositions and methods related to these conjugates.

USPTO Patent Application for Immunoconjugates

The USPTO has published a new patent application, US20260083855A1, filed by Hoffmann-La Roche Inc. The application relates to immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. This filing is part of the standard patent application process.

USPTO Patent Application: Thiazolidine Linkers for Protein-Drug Conjugates

The USPTO has published a new patent application (US20260083856A1) detailing thiazolidine linkers for protein-drug conjugates and their uses in treating diseases. The application was filed on September 11, 2025, and is scheduled for publication on March 26, 2026.

USPTO Patent Application for Anti-PD-1 Antibody-IL-2 Immunoconjugate Formulations

The USPTO has published a new patent application (US20260083857A1) for anti-PD-1 antibody-IL-2 immunoconjugate formulations. The application details stable pharmaceutical formulations comprising anti-human PD-1 antibody-modified human interleukin-2 immunoconjugates.

USPTO Patent Application: Antibody Drug Conjugate Comprising NMT Inhibitor

The USPTO has published a new patent application (US20260083858A1) related to antibody drug conjugates (ADCs) that comprise an NMT inhibitor conjugated to an antibody via a linker. The application details the inventors and abstract of the invention.

USPTO Patent Application: Sustained Transgene Expression of Modified ERT2 Peptide Fusion

The USPTO has published a patent application (US20260083859A1) detailing a novel fusion polypeptide for sustained transgene expression. The application, filed by inventors from various institutions, describes targeting constructs for inducible cell death systems using modified estrogen receptor ligand binding domains.

USPTO Patent Application for Capsid Polypeptides

The USPTO has published a new patent application (US20260083863A1) from Dyno Therapeutics, Inc. for capsid polypeptides designed for payload delivery. The application details specific polypeptide sequences and their methods of use in therapeutic applications.

USPTO Patent Application: Compositions Targeting Endothelial Cells

The USPTO has published a patent application from Harvard College detailing novel compositions for targeting endothelial cells. These compositions, which include binders, linkers, and radioactive isotopes, are intended for selective delivery to cells and treating diseases, including cancer.

USPTO Patent Application: Recombinant Human Type III Collagen for Angiogenesis

The USPTO has published a patent application (US20260083883A1) detailing recombinant human type III collagen designed to promote angiogenesis. The application describes modifications to natural type III collagen to enhance its angiogenic function and adhesion properties, potentially increasing the angiogenesis rate by over 37%.

USPTO Patent Application: Anti-DPP3 Antibody Formulations

The USPTO has published a patent application from 4TEEN4 Pharmaceuticals GmbH for formulations and dosage amounts for administering an anti-DPP3 antibody or fragment thereof to humans. The application, filed on August 26, 2025, details potential treatments for life-threatening circulatory failure conditions such as shock.

USPTO Patent Application: Cancer Treatment with Anti-CD20 Antibody and Acylfulvenes

The USPTO has published a patent application (US20260083691A1) filed by Lantern Pharma Inc. The application describes a method for treating cancer by combining an anti-CD20 antibody with acylfulvenes. This patent application is related to novel therapeutic combinations for B-cell cancers.

USPTO Patent Application: CARs for Hidradenitis Suppurativa Treatment

The USPTO has published a patent application (US20260083777A1) filed by Sonoma Biotherapeutics, Inc. The application describes chimeric antigen receptors (CARs) designed to target citrullinated polypeptides for the treatment of hidradenitis suppurativa.

USPTO Patent Application for Generating CD4 T Cells

The USPTO has published a patent application (US20260083778A1) for methods of generating CD4 T cells from progenitor cells. The application, assigned to Boston Medical Center Corporation, describes a specific differentiation process for therapeutic use.

USPTO Patent Application: Engineered Probiotics Expressing Anti-Inflammatory Molecules

The USPTO has published a patent application (US20260083783A1) from the University of Cincinnati for engineered probiotics that express anti-inflammatory molecules. The application details a genetically modified E. coli bacterium designed to produce a microbial anti-inflammatory molecule (MAM) protein.

USPTO Patent Application for CsgA-Derived Nanostructures for Antigen Delivery

The USPTO has published a patent application (US20260083834A1) for CsgA-derived nanostructures designed for antigen delivery. The application details self-assembling polypeptides conjugated to immunogens that form nanofilaments to stimulate immune responses, potentially for vaccines against various conditions.